posted
Shares outstanding 12,784,404 Fully diluted 20,874,404 Shares in escrow 4,398,965 (according to TSX web site) Net shares outstanding 8,385,439 (according to TSX web site)
COMPANY OVERVIEW
ALDA develops, manufactures and markets proprietary infection control products for the institutional and commercial health-care industry. The Company has invested five years in research and development of a novel infection control technology that has proven highly effective in killing a broad range of infectious organisms. ALDA's business objective is to be a world leader in the marketing of innovative infection control products for both wholesale and retail markets. The Company has developed a family of wide spectrum, nontoxic, biodegradable infection control products based on its patent pending T36® technology. Its first product, VIRALEX™ has been tested on over 100 infectious bacteria, viruses. VIRALEX™ kills on contact and is 100% effective in killing them all within 3 minutes.
VIRALEX™ WITH T36® ALDA’S FIRST INFECTION CONTROL PRODUCT
-VIRALEX™ is a hospital-grade, wide-spectrum, hard-surface spray disinfectant that has been tested on over 100 bacteria, viruses and fungi.
-VIRALEX™ kills all of these infectious organisms within 3 minutes, including HIV, Hepatitis B, Legionella and the Norwalk-like virus. It kills tuberculosis (TB) in 5 minutes, is 100 times more effective than the specified requirement for hospital use and exceeds the kill rate of other disinfectants on the market.
-VIRALEX™ has been granted a Health Canada DIN number and has been approved by Health Canada (HBP), the Therapeutics Product Directorate (TPD) for health safety applications and the Canadian Food Inspection Agency (CFIA) for use in food processing facilities, restaurants and other food handling establishments.
-VIRALEX™ is non-corrosive, non-caustic, non-hazardous, biodegradable, highly effective and competitively priced.
-The emergence of SARS, Norwalk virus, Avian flu, drug-resistant “superbugs”, new strains of TB and other bacterial, viral and fungal pathogens has increased the market demand for highly effective and non-toxic disinfectants.
-VIRALEX™ is used by the B.C Ambulance Service, the largest ambulance service in the world and by the National Laboratory for HIV Reference Services.
T36® FUTURE PRODUCTS
ALDA has recognized the need for and is developing a product pipeline based on its T36® infection control technology for: -commercial applications -personal use -household use -veterinary use -therapeutic treatments
Further patents are in progress and developmental work has been completed on most of these products. Clinical trials for therapeutic treatment will be undertaken as quickly as possible. Some products may require additional specific testing for regulatory process.
MARKET OPPORTUNITY
The outbreak of SARS and growing concerns with other infectious diseases has highlighted the need for more effective infection control. The worldwide market for infection control products is projected to exceed US $200 billion. Hard surface disinfectants alone command ~US $10 billion in annual sales. ALDA has successfully established its lead product VIRALEX™ in the Canadian market and is well positioned to expand its market internationally. ALDA’s T36® technology is the basis for other infection control products already in late-stage development.
ALDA’s competitive advantage resides in the ability of its proprietary T36® formulation to completely denature and destroy infectious organisms using non-toxic, non-corrosive and biodegradable ingredients. The technology is supported by a full range of efficacy and toxicology studies conducted in the USA and Canada. ALDA is currently expanding its marketing efforts to enhance corporate awareness and to ensure product recognition.
All testing of VIRALEX™ has been carried out by highly prestigious, independent institutions including: ·BC Children’s Hospital ·The John Ruedy Immunodeficiency Clinic at St. Paul’s Hospital ·The Women's Hospital of British Columbia ·The British Columbia ·Research Institute ·The Product Safety Labs in New Jersey, USA ·Viromed Laboratories Minneapolis, USA
-Develops and markets a family of biodegradable infection control products based on its proprietary T36® technology (patents pending)
-The lead product, VIRALEX™, is a hospital grade, wide-spectrum, hard surface disinfectant marketed by more than a dozen distributors.
-VIRALEX™ is available in Canada, the United Kingdom and the Caribbean. Further international distribution is anticipated in the near future.
-Used by the BC Ambulance Service, Product Distribution Centre of BC, Vancouver Fire Department, RCMP, hospitals, HIV Reference Laboratories, medical & dental clinics.
-Health Canada GMP certified facility is ready to meet anticipated sales increase.
-Recently completed $1.2 M financing to cover corporate expenses and business development.
-Experienced, professional management.
-Debt-free company with good corporate governance protocol.
VIRALEX™ with T36® technology is a state-of-the-art hospital grade disinfectant. T36® is formulated without any of the following hazardous ingredients, which even in dilution, are recognized as highly toxic, mutagenic, or carcinogenic: Peroxides, Ethers {Butyl Cellosolve}, Sulfonated salts, Glycols, Phosphoric and Sulfonic Acids, Glutaraldehydes, Bleaches, Benzene derivatives or Quaternary Ammoniums.
VIRALEX™ is a superior, non-toxic, broad spectrum disinfectant and sterilant technology for low, medium and high risk situations and for the sterilization of critical or semi-critical instrumentation. ·Environmentally friendly and 100% bio-degradable. ·Non-corrosive. No caustic chemical surfactants. ·Bacteriocidal, Virucidal, Fungicidal, Tuberculocidal, Sporicidal. ·Safe, ready-to-use hospital-grade disinfectant. ·A dilutable sanitizer plus high-level sterilant. ·Broad surface compatibility leaves no residue that can alter or adhere to treated surfaces. ·Pleasant odor and excellent detergency properties. ·Completely denatures DNA and RNA proteins and removes antigenic potential. ·Toxicology and Efficacy completed by independent laboratories in U.S. and Canada.
MANUFACTURING, MARKETING & DISTRIBUTION
-VIRALEX™ is manufactured in a Health Canada GMP-certified facility with production capability of up to 6 million units per year.
-VIRALEX™ is marketed by a growing list of distributors that supply the product to hospitals, dental offices, laboratories, chronic care facilities, medical product manufacturers, fire fighters, the military, beauty and hair salons as well as hydroelectric, water management, airlines, cruise ship and telecommunications industries.
-VIRALEX™ is also sold directly to key clients, including the RCMP, the BC Ministry of Health, community police forces, the National Laboratory for HIV Reference Services and the Product Distribution Center of BC.
-VIRALEX™ is available in 480 ml and 1 Litre trigger-spray bottles, 4x4L jugs, 20 Litre Sani-Paks and is competitively priced.
SOME VIRALEX™ USES:
ALDA Pharmaceuticals' VIRALEX™ with T36® is the company's flagship product. It is a hard-surface spray disinfectant designed to treat extensive hard surface soiling and to disinfect all washable hard and soft surfaces such as:
• Counter tops • Dental and medical chairs • Plastic or acrylic components • Electronic equipment • Tubs (pedicure, podiatric) • Walls and floors • Dental and Surgical instruments • First response vehicles • CPR equipment • Nomex, Kevlar and PBI • Laboratory glassware • Washrooms, showers • Massage and chiropractic tables
Used In: • Critical care use facilities • Hospitals • Medical and dental offices • Healthcare facilities • First aid stations • Nursing homes • Medical research labs • Biohazard spills areas • Animal (& pet) environments • "Scenes of crime" and other areas applicable to the police forces
posted
It is a new publicly traded company that already has its first product on the market featuring its infection control T36® technology in its product called VIRALEX ™. This company has very adept management that are dedicated to the success of the company and to its shareholders. Sales of the product just now started and they are taking their product internationally as well as concentrating on gaining market share in Canada. They have no debt, low outstanding shares, a good balance sheet and should experience exponential growth for the years to come. This one is definitely worth a look as it should be going places.......not one to day trade but one to put on the side and reap the rewards as management does what they are good at and let the company grow into a success and profitable company......imo
posted
As per the CEO's last interview ....the consumer version of the Viralex disinfectant should be out very soon as he said in about a months 2 -3 weeks ago....
Viralex not only kills bacteria...but also many many viruses & is safe to use without requiring gloves like other disinfectants.......many advantages to viralex!
posted
Tough break today, bad news out. However, if this is just an overreaction, than in a way it is good news...Sounds to me like they are wading back into the pool of legal battles...But it doesn't sound serious but then again what the heck do I know http://biz.yahoo.com/cnw/040630/alda_legal_action_1.html If you liked it before, is this screaming entry point at you or are you backing away
IP: Logged |
posted
the news is not bad.....after having fixed the error/dispute in the first place with the other company.....they manipulated the response from APH in their own favor........it is APH that is taking it to court and things should be decided in their favor.
I have been accumulating APH for a while and if you look at insider trading the CEO has been buying on these dips (he bought on the last dip to .15)......actually I am 99% sure he bought some today.....will be able to firm it once he files.....I had a bid earlier today.......no fill.
I doubt there will be any reaction or selling off the news.............if so people in the know will be ready to scoop up cheap shares.
I actually encourage people to sell......one mans loss is another mans gain!
posted
intersting to see that the Toronto Medical Laboratories in their Microbiology Lab Specimen Management Manual it says to use VIRALEX for leaking specimens when getting rid of them in case of possible contamination (page 1 under leaking specimen at the end) ........a very effective discenfectant against micro-organisms! http://www.microbiology.mtsinai.on.ca/manual/quality_manual/process_cont rol/specimen_management/QPCMI06001.pdf Posts: 433 | Registered: Jun 2004
| IP: Logged |
posted
ALDA Pharmaceuticals Secures Distribution Agreement in Asia Vancouver, August 5 - ALDA Pharmaceuticals Corp. (APH:TSX-V) (the “Company”) has entered into an exclusive agreement with the Linns Corporation (“Linns”) of Malaysia to distribute ViralexTM in Japan, South Korea, Taiwan and all members of the ASEAN (Association of Southeast Asian Nations) which is comprised of Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam (collectively “the Territory”). Inclusion of individual countries in the Territory is subject to submission of the required applications for approval and registration of the products by Linns.
The agreement, effective August 1, 2004, allows Linns 120 days to establish minimum sales levels. Linns also has a “Right of First Refusal” for up to 16 months to establish a joint venture with the Company to manufacture ViralexTM in the Territory.
About Linns Corporation
Linns Corporation has been operating in all ASEAN countries for 13 years, distributing a wide variety of medical products and equipment to hospitals, medical clinics and other healthcare institutions. With well-established distribution throughout the region, Linns has been very successful with the introduction of new products. Viralex™ is a complementary addition to the quality infection control products that Linns carries. These include latex examination/surgical gloves, surgical masks, lab coats and other disposable products. Thomas Tan, President and CEO, has extensive experience in medical device manufacturing and in the development of new markets leading to the growth of his company.
About ALDA Pharmaceuticals Corp.
ALDA Pharmaceuticals Corp. has developed a family of wide spectrum, non-toxic, non-corrosive, biodegradable infection control products based on its patent pending T36® technology. ALDA’s first product, Viralex™, has been tested on over 100 infectious bacteria, viruses and fungi. ViralexTM kills on contact and is 100% effective in destroying all of them, including HIV, Polio, Legionella and the Norwalk-like virus, within a 3-minute period and Tuberculosis within 5 minutes
Viralex™ has been approved by Health Canada for use as a hospital grade, surface disinfectant and by the Canadian Food Inspection Agency (CFIA) for use in restaurants and the food processing industry.
The emergence of SARS, Norwalk Virus and new strains of influenza has increased the market demand for Viralex™ as a highly effective, non-toxic and environmentally friendly disinfectant.
Terrance G. Owen, Ph.D., MBA
President, CEO and Director ALDA Pharmaceuticals Corp. www.aldacorp.com
Distribution & Sales Contact Aaron Genereaux
(604) 521- 8300 aaron1g@telus.net
Broker & Analyst Contact Scott Young
(604) 682-4029 syoung@freeformcom.com
Shareholder & Investor Contact Dan Byrne (888) 998-8886 dan@e-vestorelations.com
posted
This is very good news as this is Alda'a first distributor agreement outside Canada..... remember the CEO said on one of his last interviews that they are searching for distributors abroad and more specifally the Middle East so there could be more news to come soon.
He also said that some of these potential large distributors could require such a large amount of product to cover their territory that this alone could make Alda profitable overnight!
Lets hope the Linn Corp successfully distributes Viralex in Asia.......the Asian market is huge!
Also remeber the CEO said many weeks ago that the consumer version of Viralex is comming out very soon
E-Vestor Relations provides shareholder communications, investor relations, and information management to ALDA Pharmaceuticals Corp. and is compensated at a rate of $3,500/month.
[This message has been edited by Allstocks (edited August 14, 2004).]
VANCOUVER, Jan. 20 - ALDA Pharmaceuticals Corp. (APH:TSX-V) is pleased to announce its ASEAN distributor, Linns Corporation Sdn Bhd (“Linns”), has received clearance from the Ministry of Health’s National Pharmaceutical Control Bureau in Malaysia for the sale and marketing of Viralex™ . Malaysia, with a population of approximately 23 million, is the first of 13 ASEAN countries to which Linns will submit product registrations.
About Linns Corporation Sdn Bhd
Linns distributes a variety of medical products and equipment to hospitals, clinics and other healthcare institutions in all ASEAN countries. Linns has been very successful with the introduction of products within this well-established distribution network and Viralex™ will be a complementary addition to the quality infection control products that Linns already carries. These include latex examination/surgical gloves, surgical masks, lab coats and other disposable products. Thomas Tan, President and CEO, has extensive experience in medical device manufacturing and in the development of new markets.
About ALDA Pharmaceuticals Corp.
ALDA Pharmaceuticals Corp. has developed a family of wide spectrum, non-toxic, non-corrosive, biodegradable infection control products based on its patent pending T36® technology. The emergence of SARS, Norwalk Virus and new strains of influenza have created a market demand for a highly effective, non-toxic and environmentally friendly disinfectant. ALDA’s first product, Viralex™, has been tested on over 50 infectious bacteria, viruses and fungi. ViralexTM kills on contact and is 100% effective in destroying all of them, including HIV, Polio, Legionella and the Norwalk-like virus, within a 3-minute period and Tuberculosis within 5 minutes.
Viralex™ has been approved by Health Canada for use as a hospital grade, surface disinfectant and by the Canadian Food Inspection Agency (CFIA). Viralex™ is available through distributors in Canada, the European Union, ASEAN countries and through the worldwide web to consumers internationally. A distribution & manufacturing agreement has been completed in China. ALDA is actively seeking similar licensing arrangements in other countries.
Terrance G. Owen, Ph.D., MBA
President, CEO and Director ALDA Pharmaceuticals Corp.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
